Stock BDQM ALBIREO PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Albireo Pharma, Inc. Deutsche Boerse AG

Equities

BDQM

US01345P1066

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CAC40: in green, gains over 2% on a weekly basis
CF
CAC40: PMI and ISM data point to 22nd week of gains
CF
CAC40: 7350 in sight if rates continue to ease
CF
CAC40: breaks through 7300 pts after Bostic's comments
CF
Ipsen: acquisition of Albireo Pharma finalized
CF
French Drugmaker Ipsen Concludes Albireo Pharma Takeover
MT
ALBIREO PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
Albireo Pharma, Inc. Announces Board Changes
CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from NASDAQ Composite Index
CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P TMI Index
CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P Global BMI Index
CI
Ipsen Biopharmaceuticals, Inc. completed the acquisition of Albireo Pharma, Inc. from a group of shareholders.
CI
Ipsen Extends Tender Offer for Albireo Pharma as It Awaits US Antitrust Clearance
MT
Ipsen: extension of the deadline for its tender offer for Albireo Pharma
CF
Albireo Pharma, Inc. - FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay in Alagille Syndrome
AQ
Albireo Pharma's Bylvay Granted Priority Review for Rare Genetic Disorder Alagille Syndrome Treatment
MT
Albireo Gets FDA Priority Review of Bylvay in Alagille Syndrome
DJ
ALBIREO PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome
AQ
Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALBO Stock
  4. BDQM Stock
  5. News Albireo Pharma, Inc.